Guidelines for the Care of the Skin in Relation to Tissue Viability
Guidelines for the Care of the Skin in Relation to Tissue Viability

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Clinical Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unique Identifier</td>
<td>CL-073</td>
</tr>
<tr>
<td>Document Purpose</td>
<td>This guideline outlines the recommendations to assess and manage skin care in relation to Tissue Viability for people in all age groups.</td>
</tr>
</tbody>
</table>
| Document Author     | Jackie Stephen-Haynes, Professor and Consultant Nurse in Tissue viability  
                        Rosie Callaghan, Tissue Viability Nurse  
                        Specialist  
                        Monique Maries, Tissue Viability Nurse  
                        Suzanne Tandler, Tissue Viability Nurse  
                        Moira Evan, Tissue Viability Nurse  
                        Sue Simm, Tissue Viability Nurse |
| Target Audience     | All clinical staff within Trust    |
| Responsible Group   | Clinical Policies Group            |
| Date Ratified       | 8th January 2015                   |
| Expiry Date         | 8th January 2018                   |

The validity of this policy is only assured when viewed via the Worcestershire Health and Care NHS Trust website (hacw.nhs.uk). If this document is printed into hard copy or saved to another location, its validity must be checked against the unique identifier number on the internet version. The internet version is the definitive version.

If you would like this document in other languages or formats (i.e. large print), please contact the Communications Team on 01905 760020 or email communications@hacw.nhs.uk.
<table>
<thead>
<tr>
<th>Version</th>
<th>Circulation Date</th>
<th>Job Title of Person/Name of Group circulated to</th>
<th>Brief Summary of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>25/11/2014</td>
<td>WHCT Tissue Viability County Team members,</td>
<td>Remove staff identifiable information, NMC reference added, correction of grammatical errors.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WHCT Tissue Viability Link Nurses,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associate Director of Nursing,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Director of Quality,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultant Nurse Infection Prevention</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and Control,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paediatric Lead,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Services Locality Manager,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Practice development and Service</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lead- Mental Health,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Community Hospital Matron,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Services Operational Lead,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head of Quality Governance, specialist</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>practitioner facilitator.</td>
<td></td>
</tr>
<tr>
<td>02</td>
<td>16/12/2014</td>
<td>Clinical Policies Group</td>
<td>Formatting</td>
</tr>
<tr>
<td>03</td>
<td>22.01.15</td>
<td>Clinical Policies Administrator</td>
<td>Updating of Appendix 1</td>
</tr>
</tbody>
</table>

**Accessibility**

Interpreting and Translation services are provided for Worcestershire Health and Care NHS Trust including:

- Face to face interpreting;
- Instant telephone interpreting;
- Document translation; and
- British Sign Language interpreting.

Please refer to the intranet page: [http://nww.hacw.nhs.uk/a-z/services/translation-services/](http://nww.hacw.nhs.uk/a-z/services/translation-services/) for full details of the service, how to book and associated costs.

**Training and Development**

Worcestershire Health and Care NHS Trust recognises the importance of ensuring that its workforce has every opportunity to access relevant training. The Trust is committed to the provision of training and development opportunities that are in support of service needs and meet responsibilities for the provision of mandatory and statutory training.

All staff employed by the Trust are required to attend the mandatory and statutory training that is relevant to their role and to ensure they meet their own continuous professional development.
Other guidelines to be referred to:
Consent to Treatment Policy
Clinical Record Keeping Guidelines
Wound Management Formulary
Infection Control Guideline
Wound Assessment and Management Guideline
Nice Guideline Improving outcomes for people for skin tumours Feb 2006
Nice PUP guidelines 2014
NICE Nutrition 2006
Worcestershire Area Prescribing Committee Dermatology Guidelines
## CONTENTS

1. Introduction ................................................. 5  
2. Purpose .................................................. 6  
3. Scope ..................................................... 6  
4. Training/Competencies ................................. 6  
5. Skin Assessment and Documentation .............. 6  
6. Skin Assessment and Pressure Ulcer Prevention ... 7  
7. Skin Care ............................................... 8  
8. Skin Cleansing ............................................ 8  
9. General Hygiene ......................................... 9  
10. Common Skin Conditions ............................. 11  
11. Emollients ............................................. 14  
12. Staff Education ......................................... 18  
13. Clinical Audit .......................................... 19  
14. References ............................................ 19  

**Appendix 1**  Skin Assessment Form ..................... 21  
**Appendix 2**  Skin Integrity Model (SIM) Tool .......... 23  
**Appendix 3**  Staff guide to the classification, assessment and management of Moisture lesions and Pressure Ulcers (Moisture or Pressure Tool MOPT) 25  
**Appendix 4**  Patient guide to barrier protection ........ 27  

**Equality Analysis** ........................................ 29
1. Introduction

a. Skin is the largest organ of the body, being 10% of the body mass (White & Butcher 2006). It has the primary function of providing a barrier between the internal body structures and the environment. Several other functions include:

- Secretion;
- Thermoregulation;
- Absorption;
- Protection;
- Elimination;
- Sensation;
- Production of vitamin D; and
- Production of melanin.

b. The structure and function of an older person's skin reflects the cumulative effects of 'programmed' ageing and added ageing (Talarico 1998). 'Programmed' ageing is the true biological process, whereas 'added' ageing refers to the damage caused from exposure to the environment.

c. Elderly skin is less elastic, drier and the tissue mass is greatly reduced. The efficient function of the skin is often compromised in people whose mobility is restricted i.e. bed bound, wheel chair user, inability to move or alter position often enough. Skin inspection should occur on a daily basis however; frequency should be determined in response to changes noted in the individual's conditions, which may increase or decrease the frequency.

d. Care of the skin is of prime importance when caring for any patient. If skin is compromised it can have a dramatic effect on a person's well being. Regular reassessment of the patients' skin and documentation of the findings forms an essential part of their holistic care.

e. When approaching assessment healthcare professionals/carers need to consider several factors, which may compromise healthy skin. These are both intrinsic and extrinsic:

<table>
<thead>
<tr>
<th>Intrinsic</th>
<th>Extrinsic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dryness</td>
<td>Continence</td>
</tr>
<tr>
<td>Atrophy</td>
<td>Smoking</td>
</tr>
<tr>
<td>Reduced elasticity</td>
<td>Environmental pollutants</td>
</tr>
<tr>
<td>Wrinkling</td>
<td>Ultra Violet Light (UVL)</td>
</tr>
<tr>
<td>Pigmented and other blemishes</td>
<td>Radiotherapy/chemotherapy</td>
</tr>
<tr>
<td>Chronic venous/arterial insufficiency</td>
<td>Decreased mobility</td>
</tr>
<tr>
<td>Known skin conditions</td>
<td>Chronic illness</td>
</tr>
<tr>
<td>Previous skin damage</td>
<td>Dehydration</td>
</tr>
<tr>
<td></td>
<td>Poor nutrition</td>
</tr>
<tr>
<td></td>
<td>Drug therapy</td>
</tr>
<tr>
<td></td>
<td>Wound</td>
</tr>
<tr>
<td></td>
<td>High level of exudate</td>
</tr>
</tbody>
</table>
2. **Purpose of this Guideline/Procedure**

   The aim of this guideline is to provide advice for clinicians on skin care in relation to tissue viability. This guideline incorporates all patients across the Worcestershire Health and Care NHS Trust with tissue viability needs.

3. **Scope**

   The guideline applies to all staff caring for patients in the assessment, prevention and management of skin care in relation to tissue viability. It is designed to ensure patients skin is assessed and preventative strategies are implemented and where there is a skin care in tissue viability need, this is optimum treatment with an evidence base. This guideline outlines the recommendations to assess and manage skin care in relation to Tissue Viability for people in all age groups. The guideline is to be used by all staff employed by the Worcestershire Health and Care Trust who may be engaged in the assessment and management of skin care in relation to Tissue Viability. It is recommended for use by all Care Homes across Worcestershire.

4. **Training/ Competencies**

   Registered Health care professionals and supervised Student Nurses who can demonstrate practical competence in skin assessment in relation to Tissue Viability. An educational programme, incorporating internal courses and accredited degree level study, is available. Informal and formal assessment is undertaken. This forms part of the individuals overall professional development (Knowledge and Skills Framework).

5. **Skin Assessment and Documentation**

   a. When a patient’s skin changes from its normal appearance or the skin integrity is breached, it is important that an early assessment is undertaken and interventions instigated. Peri-wound skin has a compromised barrier due to the underlying tissue inflammation and is therefore more susceptible to breakdown (Bishop et al 2003).

   b. The following factors should be considered (Newton and Cameron 2003):

      - Family history of skin problems;
      - The effect of ageing;
      - The impact of the skin;
      - The effects of steroids;
      - The effects of chronic illness. Ie diabetes, rheumatoid disease, congestive cardiac failure;
      - Mobility and positioning of the patient;
      - Continence status;
      - The presence of a wound and the impact its clinical characteristics may have on skin integrity;
      - What treatments or actions have influenced the skin integrity; and
      - The length of time the skin problem has been present and any trends in recurrence.
c. Several factors relating to the surrounding skin of the wound may be recorded on the Skin Assessment chart (See Skin assessment chart appendix 1) and are also included in the wound management assessment tool, see Wound Management Guidelines) including:

- Erythema (distance);
- Blanching/non blanching;
- Excoriated;
- Macerated;
- Dry/Scaly;
- Oedema;
- Healthy,
- Fragile,
- Skin organ failure/ end of life
- Skin stripping

d. Perspiration and wound drainage can also make the skin more vulnerable to injury. When the skin is damaged it is more susceptible to bacterial and fungal infections. Please note that swabs or a fungal scrape may need to be taken to ascertain what bacteria/fungal infections are present so that appropriate treatment can be recommended, if necessary.

6. **Skin Assessment and Pressure Ulcer Prevention**

a. Patients deemed at risk should have their skin assessed regularly with the frequency prescribed and titrated to vulnerability level and in response to any health condition change. On-going assessment is necessary to detect the early signs of pressure damage (EPUAP 2014). Individuals and carers should also be encouraged to inspect the skin and take responsibility for its condition (NICE 2014).

**The signs alerting damage presence include:**

- persistent erythema (reddening)
- non-blanching hyperaemia (capillaries do not empty and refill)
- blisters (superficial)
- localised heat (warm to touch)
- localised oedema (swelling)
- Induration (hardness)
- purplish/bluish localised areas in those with dark skin

b. Recognising reddened areas of the skin is a significant factor in identifying the earliest signs of pressure damage and is an indication that further action and preventative nursing care is required.

c. Where appropriate, patients should be asked to identify areas of discomfort or pain as this may be a pre cursor to tissue breakdown. Additionally the skin should be observed for pressure damage created by devices (EPUAP 2014) such as continence care devices.

Visual skin assessment and additional details such as discomfort or pain should be documented to allow monitoring of the progress of the individual and to aid effective communication between professionals. Patients unable to feel pain due to sensory loss or unable to communicate their pain should be more frequently and closely observed for early signs of damage.
Skin assessment is to be undertaken as part of the SSKIN Bundle and documented on appendix1.

Re-assess patients skin on an on-going basis according to individual need and general condition change. This is dependent upon the general condition of the patient and reassessment may be required in as little time as 6 hours. The maximum agreed period before general re-assessment for those on the District Nurse caseload is every 6 months and therefore re-assessment may be up to a maximum of 6 months.

7. Skin care

Reddened Skin: massage should never be undertaken in the presence of acute inflammation (reddening) due to the risk of increasing the existing damage to underlying blood vessels and potentially separating fragile skin layers. Washing of the area and cream applications should also be undertaken with care.

Dry Skin: is less tolerant to tissue distortion (stretching) and is thus more vulnerable to breakdown (Allman et 1995). Emollient should be applied, as available in the Wound Management Formulary to maintain the suppleness of the skin and reduce the risk of breaks/cracks forming. Barrier creams are also available when suppleness and a protective barrier is required. Skin should always be dried thoroughly after washing prior to application of products.

Excessively Moist Skin: prolonged exposure to excessive moisture (urine, faeces, exudate or sweat) increases the risk of damage from maceration, friction and shear forces (Defloor 1999). Skin that is exposed to or at risk of exposure to excessive moisture should be protected with a barrier forming product as available in the Wound Management Formulary

8. Skin Cleansing

a. Different parts of the body require different cleansing methods and will be considered in relation to incontinence and soiling, general hygiene and care of the lower limbs.

8.1 Incontinence associated dermatitis and Soiling

a. Incontinence-associated dermatitis is the clinical manifestation of inflammation and erosion of the skin caused by prolonged exposure to various sources of moisture, including faeces, urine, perspiration and wound exudate, is known as incontinence-associated dermatitis (Gray et al 2007) but may also be referred to as moisture lesions. Incontinence Associated Dermatitis is most commonly experienced by people with faecal and urinary incontinence, as this causes the skins PH to become more alkaline causing skin irritation and breakdown (Langemo et al 2011).

b. Prolonged excessive moisture of the skin can lead to inflammation and dermatitis (Voegeli 2012), an increase in moisture leads to maceration of the skin intensifying the risk of damage from friction and pressure (Mayrovitz and Sims 2001). If left untreated symptoms may present as inflammation of the skin, redness and in severe cases swelling and blisters.

c. It is vital to differentiate between incontinence associated dermatitis and the presence of pressure damage, incorrect assessment can lead to the formation of inappropriate care and treatment. Ultimately this will result in a negative impact on the patients experience (Beeckman et al 2010).
Incontinence associated dermatitis is most likely to be located on any part of the perineal area (not over bony prominences), tends to be superficial, involving only the epidermis and the upper dermal layers (NPUAP 2009). Incontinence associated dermatitis tends not to be localised, with the edges of lesions usually irregular and the surrounding area reddened as a result of the irritating nature of incontinence (Beeckman et al 2010). See appendix 3 for Staff guide to the classification, assessment and management of Moisture lesions and Pressure ulcers (Moisture or Pressure Tool MOPT).

d. To prevent the effects of incontinence associated dermatitis it is recommended that a comprehensive holistic continence assessment and documentation is undertaken with the patient. This is to ensure all causative factors eg, faecal or urinary incontinence have been addressed in the first instance. It is also recommended that an appropriate skin cleansing regime has been adopted incorporating the use of a suitable skin barrier product (Nix and Haugen, 2010).

e. The Agency for Health Care Policy and Prevention (AHCPR, 1992) recommend that skin cleansing should occur at the time of soiling. Mild cleansing agents and warm water should be used rather than soap as this can have a drying effect and therefore cause more irritation. The area should be dried thoroughly; moisturiser/emollients should be applied to dry areas of skin using the dot method, whereby small amounts (dots) of moisturiser are initially applied over the whole area to be covered. Skin rubbing and massage, particularly over bony prominence should be avoided as it can cause friction damage (Dyson, 1978, Nice 2005).

f. The aim of the treatment should be to minimise exposure to urine/faeces and reduce exposure to moisture and friction. It has been demonstrated that urine and faeces contain waste products that can irritate and chemically burn skin (Chilvers, 1999). Suitable barrier preparations may be needed (Appendix 4).

9. General hygiene

a. The use of soap products and detergents i.e. bars of soap, bubble bath/foam can strip essential lipids from the epidermal barrier. Many of these products are alcohol based which also has a drying effect. The pH level of normal skin is 5.5. Most soap is highly alkaline and removes the natural oils that keep the skin hydrated. An added hazard when using bars of soap is the risk of cross infection. Use of a soap substitute by older people reduces the incidence of dryness, redness and flaking of their skins (Hardy, 1990). Staff should advise patients that a soap substitute such as Aqueous cream will not produce lather. However (Hardy, 1996) suggests should a person wish to continue using soap a non-perfumed, hexachlorophene free super fatted soap (such as Dove Sensitive) should be used.

b. It is advisable not to use preparations that contain preservatives, fragrances, alcohol, perfumed moisturisers, and lanolin as these can all potentially cause sensitivity.

9.1 Care of the lower limb

a. For patients with lower limb ulceration soak leg in mains drawn tap-water in a plastic lined bucket for 10 mins (see WHCT Leg Ulcer policy and guidelines). Caution should be exercised for those with confirmed arterial leg ulceration as these may need to be kept dry.
b. It is most important that if a patient’s skin condition is a cause for concern and is not improving to refer for a Consultant Dermatologist’s opinion as there may be an underlying skin disease that has not been diagnosed.

9.2 Skin Care Relating to the Lower Limb and Feet

a. Wash daily wherever possible using pH neutral soap substitute and dry thoroughly, particularly between the toes. Avoid using scented products.

b. Apply emollients at least once daily. Avoid the area between toes.

c. Avoid the use of talc.

d. Examine feet daily and if padding is in situ remove to allow examination of skin underneath.

e. Avoid soaking the feet.

f. Avoid use of proprietary corn preparations and plasters.

g. Treat areas of fungal infection as this can lead to subsequent infection in other areas.

9.3 Skin Care Relating to Barrier Protection

a. Changes in skin moisture level can lead to a reduction in the skin’s barrier function, thereby allowing the penetration of irritants. The use of a barrier preparation may be beneficial when used in conjunction with personal hygiene.

b. The barrier cream and film in the wound management formulary is:
   - Sorbaderm barrier film and cream

c. Sorbaderm barrier cream will not “clog” the continence pad and should be applied very sparingly every 3rd wash. A 10 pence coin size would be sufficient cream; over application leads to the skin feeling waxy. If waxy skin occurs do not apply further cream as there is sufficient already present.

9.4 Skin Care in Relation to Lymphoedema

a. Maintenance of skin integrity and the management of skin problems are very important to avoid the risk of infection.

b. General principles of skin care include:
   - Wash skin daily, wherever possible, using pH neutral soap or a soap substitute, and dry thoroughly. Avoid scented products.
   - Legs should be washed with tap water soaked in a lined bucket. [Best Practice For The Management of Lymphoedema]
   - Ensure skin folds, if present, are clean and dry
   - Apply Emollients at least once daily.
   - The WHCT Lymphoedema Clinic recommends Aqueous cream or 50/50 paraffin if the skin is dry.
   - If the client has a particular skin problem, then this should be discussed with the clinic staff who will recommend appropriate treatment.
   - If the affected limb is injured wash thoroughly and apply antiseptic cream straight away. Observe for redness, heat, more swelling, pain and general malaise - contact the GP/Nurse Practitioner as antibiotics may need to be prescribed.
   - Patients with Lymphoedema are at risk of fungal infection and should be monitored for cellulites and treated with appropriate medication.
Avoid sunburn, use a high factor sun-block if the skin is exposed.
Insect repellent spray is also advisable for people with Lymphoedema.

9.5 Lymphorrhoea management
a. Medical review to determine the underlying cause.
b. Surrounding skin should be protected with emollient, and a non adherent absorbent dressing applied to the weeping skin. Multi-layered Lymphoedema bandaging then applied to reduce the underlying Lymphoedema, and reduce the Lymphorrhoea. The bandaging will need to be changed frequently to avoid maceration of the skin.

10 Common Skin Conditions

10.1 Eczema
a. The literal Greek meaning of eczema is to ‘boil over’ (Collins et al 2002). Eczema is an inflammatory disorder of the skin, which causes dryness itching, redness and excoriation. There are many types of eczema that can affect different parts of the body, and these conditions can vary in their severity, from mild to severe. Eczema, (also known as dermatitis) may be described as wet or dry, localised or general in nature and may be explained as endogenous (linked to internal factors) or exogenous (reaction to an external stimulus). In practice, patients with endogenous eczema will also be susceptible to irritation/aggravation by external factors.
b. A common form of eczema found in a large number of older adults is Varicose/Gravitational/Stasis eczema (National Eczema Society 2005). It is associated with poor venous return and is known to affect those with varicose veins, obesity, lower limb oedema, phlebitis or previous deep vein thrombosis. A higher percentage of women compared to men are likely to suffer with varicose eczema due to increased pressure on the deep pelvic and leg veins during pregnancy.
c. Common forms of Eczema in the elderly:

| Gravitational Eczema | Known as varicose eczema.  
Associated with poor venous return  
Caused by increase in pressure within the veins  
(High pressure damages the small blood vessels, releasing red blood cells into the skin, leading to pigmentation. The skin becomes thin breaks easily and becomes flaky, inflamed and itchy.) |
| Discoid Eczema | Known as nummular eczema  
Itchy, symmetrical, coin shaped lesions. Begins as slight bump on the surface and then patches begin to weep. This can lead to scaling, itching, crusts and infection. |
| Asteatotic Eczema | Eczema due to dry skin and often frequent use of soaps, with the appearance of dried cracked riverbed. It occurs on the legs most frequently and often causes tiny fissures, bleeding, scaling, itching and soreness. |

10.2 Contact Dermatitis
a. Contact Dermatitis occurs when there is an inflammatory reaction of the skin to an external agent. The severity of the reaction will vary according to
the method of exposure, the area of skin involved and the substance/concentration used. These can include topically applied creams/lotions, dressings/bandages, soap etc.

b. There are two main causes of contact dermatitis: irritants and allergens (British Skin Foundation 2007).

c. Irritants - substances that strip the skin of its natural oils, and cause dermatitis to develop if contacted frequently and without skin protection. When this happens, the skin changes are known as an irritant contact dermatitis. The most important factor in causing this type of contact dermatitis is the amount of irritants to which an individual is exposed.

d. Allergens - immune systems can develop a specific reaction after exposure to an external agent. Good examples include substances such as nickel, rubber, and perfumes or preservatives used in some creams and cosmetics. This type of dermatitis is called an allergic contact dermatitis. It is not known why some people who are exposed to these allergens develop it while others do not.

### 10.3 Folliculitis

a. Folliculitis is the name given to skin conditions where there are inflamed hair follicles. The result is a tender red spot, often with a surface pustule at the base of each affected hair. Folliculitis can be due to infection, occlusion, irritation and specific skin diseases. The use of emollients/moisturising creams can cause folliculitis and when used should always be applied in the direction of natural hair growth.

### 10.4 Candida

a. Candida is the name for a group of yeasts (a type of fungus) that commonly infect the skin and often occur in moist skin folds. These areas include:

b. Between toes, web spaces of the hands (skin is moist, white, peeling and uncomfortable).

c. Under breasts/in the groin/between the buttocks (the onset of bright red irritable skin is usually abrupt and may peel and the moist skin fold is cracked and sore. There are usually tiny surface "satellite" spots, blisters or pustules).

d. NB. If a candida infection is suspected it is important to consult a nurse, doctor or pharmacist for examination, advice and appropriate treatment.

### 10.5 Cellulitis

a. Cellulitis is an inflammatory bacterial infection of the skin and subcutaneous tissue, which will require assessment by a health care professional and antibiotic therapy. Classic characteristics of cellulitis in an acute wound are: pain and tenderness, redness, swelling and heat (Morison et al 1999) and often associated fever, malaise and other systemic symptoms.

b. Erisepilas is a more superficial infection than cellulites, almost exclusively streptococcal, and characteristically with a more well-defined border. Management is the same as for cellulites.

c. However in an infected chronic wound (leg ulcer, pressure ulcer) the situation is slightly more complicated. Diagnosis may depend on other host reactions or clinical signs (Cutting and Harding 1994). These include increased wetness, changes in pain, and change in appearance of granulation tissue, odour and presence of pus (although not commonly found in chronic wounds).
10.6 Pruritis

a. Pruritis (generalised itch) is a frustrating and sometimes debilitating condition that can impact severely on an individual's quality of life. Thorough assessment is essential to establish a possible cause which can often be found to be linked to an underlying skin condition or systemic disease. In some individuals however a cause cannot be identified (Gawkrodger 1992). Avoidance of potential irritants such as perfumes, soaps and powders should be encouraged whilst emollients and use of topical antipruritics may be beneficial.

11. Emollients

a. Emollient is the medical term for a non-cosmetic moisturiser. They soothe, smooth and hydrate the skin and are indicated for all dry or scaling disorders. Their effects are short-lived and they should be applied frequently, even after improvement occurs. Emollients are useful in dry and eczematous disorders - light emollients are suitable for many patients with dry skin, but a wide range of more greasy preparations are available.

b. The severity of the condition, patient preference and site of application will often guide the choice of emollient and they should be applied in the direction of hair growth. The Skin Care Campagn (SCC 2009) advocates that patients should be given the widest possible choice of skin treatments which should be accompanied by a demonstration of the application technique.

c. Patients with eczema should use moisturisers in the bath (taking care about slipping), shower and direct to the skin.
   - Avoid soap and use bath or shower moisturisers.
   - Bland moisturisers should be applied directly to the skin.
   - Control inflammation with corticosteroid ointments or creams.

d. If Infected – Bacterial infection may be signified by weeping, pustules, crusts, fever, malaise, worsening eczema, failure to respond to therapy. Refer to GP and Area Prescribing Committee Dermatology Guidelines.

e. Ointments are the most greasy emollients, have optimum skin penetration and are the most effective moisturisers.

f. Creams have a higher water content, contain less grease and are therefore easier to apply. They may contain preservatives which can cause irritation or occasionally allergic reactions.

g. Lotions are the least effective as they have the least oil content. These are most commonly used in patients with hairy skin where there is a tendency to folliculitis.

h. Bath oils are designed to disperse into fine droplet suspensions when added to bath water and are designed to coat the immersed skin. They do not contain water and are self-preserving (Kingsley 2005).

i. Pastes are ointments with insoluble ingredients are very useful for soothing fissures.

j. Emollients may contain therapeutic additives, such as urea which can effectively hydrate the skin. However evidence for their benefit is limited.

k. Where possible the simplest emollient with the least additives (preservatives and fragrances) is recommended (Me Rec 1998). NB Preparations containing an antibacterial should be avoided unless infection is present or is a frequent complication.

l. A thin and even layer of emollient should be applied that covers the area and can be gently smoothed into the skin so that it glistens (National Eczema Society 2005). Downward stroking motions should be used in order to avoid Folliculitis.
11.1 Moisturisers and Emollients

a. As a soap substitute:
   - Aqueous Cream 500 gm;
   - Diprobase Cream 500 gm;
   - Oilatum Shower Emollient 125 gm;
   - Doublebase Shower emollient;
   - Emulsifying Ointment;
   - Epaderm;
   - E45 wash 250 ml; and
   - If infected – Dermol 200 or 500.

b. In The Bath:
   - Oilatum Emollient 500 ml;
   - Balneum 500 ml;
   - Emulsiderm 300ml/1L;
   - Cetraben Bath emollient;
   - Doublebase Bath emollient;
   - Alpha-Keri Bath Oil 240ml/480ml;
   - Diprobath 400 ml;
   - Aveeno Bath Oil 250 ml;
   - Hydromol 350 ml/1L;
   - If infected – Oilatum Plus 500 ml, Dermol 500/600 500 ml
   - Oilatum Plus is only a bath product and must not be applied directly to the skin as it would be irritant in an undiluted form.

11.2 Moisturisers/emollients used after washing/bathing and at least 3 times daily

a. Creams:
   - Cetraben;
   - Diprobase cream;
   - Doublebase;
   - Aveeno cream;
   - Unguentum Merck;
   - Hydromol cream;
   - Neutrogena Dermatological cream; and
   - Hydrous ointment (oily cream).

b. Ointments:
   - Epaderm (greasy but very effective) or Hydromol ointment;
   - White Soft Paraffin/Liquid Paraffin 50:50 (greasy but very effective) 500 gm;
- Emulsifying Ointment; or
- If infected – Dermol 500 as soap substitute, Dermol 600 to bath, Dermol 200 shower emollient.

### 11.3 More detailed information

<table>
<thead>
<tr>
<th>Product</th>
<th>Uses</th>
<th>Ingredients</th>
<th>Excipients</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aqueous Cream</td>
<td>Light emollient. Can be used as soap substitute</td>
<td>Emulsifying ointment 30%, phenoxyethanol 1% in freshly boiled and cooled purified water</td>
<td>Excipients include cetostearyl alcohol</td>
<td>Use as soap substitute. Consider cross infection when using tubs. Use a spatula or a clean gloved hand</td>
</tr>
<tr>
<td>Emulsifying Ointment *</td>
<td>Use as a soap substitute</td>
<td>Emulsifying wax 30%, white soft paraffin 50%, liquid paraffin 20%</td>
<td>Excipients include cetostearyl alcohol</td>
<td>Use as soap substitute. Consider cross infection when using tubs. Use a spatula or a clean gloved hand</td>
</tr>
<tr>
<td>Diprobase Cream</td>
<td>Indicated for dry skin conditions and soap substitute</td>
<td>Contains Cetomacrogol 2.25%, cetostearyl alcohol 7.2%, liquid paraffin 6%, white soft paraffin 15%</td>
<td>Excipients include cetostearyl alcohol, chlorocresol</td>
<td>In pump dispenser</td>
</tr>
<tr>
<td>50/50 Ointment *</td>
<td>Indicated for use as an emollient</td>
<td>liquid paraffin 50%, white soft paraffin 50%</td>
<td>Excipients-none</td>
<td>Use as an emollient</td>
</tr>
<tr>
<td>Sorbaderm Cream and Non sting barrier film</td>
<td>Protection from body fluids including wound exudate Protection from tapes and dressings</td>
<td>Apply cream very sparingly after every third episode of incontinence (NB Cream is not no-sting) Film will aid adhesion of tapes and adhesive dressings, creams will not prevent dressings from sticking</td>
<td>Infected skin Very fragile skin, as Cavilon film will aid adhesion of the dressing</td>
<td>Cream 2g, 28g &amp; 92g Film 1ml, 3ml, 28ml WILL NOT BLOCK INCONTINENCEPADS</td>
</tr>
<tr>
<td>Conotrane</td>
<td>use for nappy/urinary rash</td>
<td>0.1% dimeticone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetraben Emollient</td>
<td>Inflamed, damaged, dry or chapped skin including eczema</td>
<td>Contains White soft paraffin 13.2% and light liquid paraffin 10.5%</td>
<td>Excipients include parabens cetostearyl alcohol</td>
<td>In pump dispenser</td>
</tr>
<tr>
<td>Doublebase (Dermal)</td>
<td>Use a soap substitute and moisturiser</td>
<td>Contains Isopropyl myristate 15%, liquid paraffin 15%</td>
<td>Excipients-none</td>
<td>In pump dispenser</td>
</tr>
</tbody>
</table>
Epaderm | Indicated for use as emollient or soap substitute | Contains emulsifying wax 30% yellow soft paraffin 30% liquid paraffin 40% | Exipients include cetostearyl alcohol | Oil based - need to consider protecting clothing

Dermol 200 shower, 500 lotion or 600 bath | Antiseptics | Benzalkonium | Cetostearyl alcohol | Used when patient at risk of recurrent infection.

*Paraffin products are FLAMMABLE.

11.4 Product container contamination

The following list supports best practices in preventing container contamination (Kingsley 2005)

<table>
<thead>
<tr>
<th>Do</th>
<th>Do not</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep it for the same patient</td>
<td>Return to the store cupboard</td>
</tr>
<tr>
<td>Label it with the name and start date</td>
<td>Use longer than pharmacist or manufacturer recommends</td>
</tr>
<tr>
<td>Use clean non-sterile gloves</td>
<td>Apply product to skin and return to the receptacle for more without washing hands or changing gloves</td>
</tr>
<tr>
<td>Decant product into a gallipot or convenient clean surface</td>
<td>Return the gallipot to the main receptacle</td>
</tr>
<tr>
<td>When using a multi-use pot use a clean spatula, gloved hand</td>
<td>Wipe the nozzle on the skin</td>
</tr>
<tr>
<td>Re-seal the main container before proceeding to apply to the skin</td>
<td>Handle the tube or pot with unclean gloves</td>
</tr>
<tr>
<td>Work the product onto the skin from the gallipot</td>
<td>Use old products ‘found in the cupboard’ or damaged containers</td>
</tr>
</tbody>
</table>

11.5 Topical Corticosteroid Preparations

a. Topical Corticosteroid Creams/Ointments will settle the inflammation and itching of eczema when it is active. They come in different strengths/potencies. Topical corticosteroid preparations should be used in combination with moisturisers in a planned skin care ’regime’.

b. A medical practitioner or supplementary prescriber is required to prescribe the preparation and potency used.

c. Steroid ointments should be used rather than creams as ointments are oil based and contain fewer preservatives than creams. Creams can be used for weeping eczema or on the face.

d. Topical corticosteroids are safe as long as they are used in the right way. Use the right strength to improve a flare up; stop using them or reduce their strength once the eczema has improved. Stopping topical steroids abruptly may allow the eczema to flare up (rebound) again; therefore reduce applications gradually and continue using them on 1-2 days a week for approximately two weeks after eczema has settled.
e. Skin thinning from topical corticosteroid preparations should not be a problem if they are used properly. It usually arises when a potent steroid has been used for too long, or in a ‘delicate’ area where the skin is thin. Weaker topical steroids should be used where the skin is particularly thin, such as on the face, eyelids, and armpits: stronger steroids can be used at other sites.

f. Steroids are classed as mild, moderate, potent and very potent; and it is sometimes recommended to have a range of suitable creams available of different strengths and to move up and down the steroid ladder, depending on how the skin responds to treatment. In this way stronger preparations may be used while skin is inflamed and milder ones as the eczema settles (British Association of Dermatologists 2006).

11.6 Cautions/Contra-indications

a. Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and the use of potent or very potent corticosteroids except under specialist supervision. Extreme CAUTION is required in treating infants, including nappy rash—treatment should be limited to 5–7 days.

b. Topical corticosteroids are contra-indicated in untreated bacterial, fungal, or viral skin lesions, in acne rosacea, and in perioral dermatitis; potent corticosteroids are contra-indicated in widespread plaque psoriasis. (BNF2009)

11.7 Side-effects

a. Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing’s syndrome, depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous (skin fold) areas and is increased by occlusion.

b. Local side-effects include:
   - Spread and worsening of untreated infection;
   - Thinning of the skin which may be restored over a period after stopping treatment but the original structure may never return;
   - Irreversible striae atrophicae and telangiectasia;
   - Contact dermatitis;
   - Perioral dermatitis;
   - Acne, or worsening of acne or acne rosacea;
   - Mild depigmentation which may be reversible;
   - Hypertrichosis also reported
   - Cataracts and glaucoma if used around the eye.

c. In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective (BNF2014).
11.8 Corticosteroid Potency Ladder and Formulary.

<table>
<thead>
<tr>
<th>Potency</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild:</td>
<td>Hydrocortisone 1%</td>
</tr>
<tr>
<td>Moderately Potent:</td>
<td>Clobetasone (Eumovate)</td>
</tr>
<tr>
<td></td>
<td>Betamethasone 1 in 4 (Betnovate RD)</td>
</tr>
<tr>
<td>Potent:</td>
<td>Betamethasone (Betnovate)</td>
</tr>
<tr>
<td></td>
<td>Fluocinolone (Synalar)</td>
</tr>
<tr>
<td></td>
<td>Fluocinonide (Metosyn)</td>
</tr>
<tr>
<td></td>
<td>Hydrocortisone butyrate (Locoid)</td>
</tr>
<tr>
<td></td>
<td>Mometasone (Elocon)</td>
</tr>
<tr>
<td></td>
<td>Fluticasone (Cutivate)</td>
</tr>
<tr>
<td>Very Potent:</td>
<td>Clobetasol (Dermovate)</td>
</tr>
<tr>
<td></td>
<td>Diflucortolone (Nerisone Forte)</td>
</tr>
</tbody>
</table>

11.9 Application

a. Topical corticosteroid preparations should be applied no more frequently than twice daily; once a day is often sufficient. Topical corticosteroids should be spread thinly on the skin; the length of cream or ointment expelled from a tube may be used to specify the quantity to be applied to a given area of skin. This length can be measured in terms of a **fingertip unit** (the distance from the tip of the adult index finger to the first crease). One fingertip unit (approximately 500 mg) is sufficient to cover an area that is twice that of the flat adult palm. The use of emollients will reduce the need for topical steroids and emollient usage should generally exceed steroid use by 10 to 1 in terms of quantity (Lawton 2009).

b. The fingertip unit method:
   - FTU = Fingertip unit (Adult).
   - 1 FTU = ½g of cream or ointment.
   - Measurement based on 5mm nozzle

<table>
<thead>
<tr>
<th>Face Neck and</th>
<th>One Arm</th>
<th>One Hand</th>
<th>One Leg</th>
<th>One Foot</th>
<th>Trunk (Front)</th>
<th>Trunk (Back)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2½</td>
<td>3</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>7</td>
<td>7</td>
</tr>
</tbody>
</table>

11.10 Maintenance, re-assessment and review of on-going treatment

a. The GP should monitor amount of steroid prescribed, and refer to the Dermatologist if they consider too much/ too potent steroid is being used in order to keep the condition under control.

12. Staff Education

Staff will be offered education relating to skincare and are expected to maintain evidence of their own up to date, evidence-based knowledge and skills as part of their professional registration and/or development and will be available within WHCT.
13. **Clinical Audit**

An annual Audit of prescribing of creams will be undertaken as part of the wound management review and the findings presented to the Trust Board, Locality Managers, Clinical Governance and County Tissue Viability Team.

14. **References**


Langemo, D. Hanson, D. Hunter, S. Thompson, P. Oh IE (2011) Incontinence and incontinence associated dermatitis. Advances in Skin and Wound care. 24,3, 126-140.


Worcestershire Dermatology Guidelines. 2014

# Appendix 1 Pressure Ulcer Prevention and Skin Assessment Form

**WARD:** __________________________

Mark each area of pressure damage with an ‘X’ on the body map and number /date each area of damage/pressure ulcer:

**Most common location of pressure ulcers**
- Back of head
- Ears
- Shoulders
- Elbow
- Lower Back
- Sacrum
- Ischial Tuberosities
- Hips
- Between knees
- Malleolus
- Heels

Please consider all areas of the body:

- Previous history of pressure ulcer
  - Yes
  - No

- Location _________________________

- Waterlow Score ______________________

---

### Focus of Care

<table>
<thead>
<tr>
<th>Focus of Care</th>
<th>Skin</th>
<th>Keep moving</th>
<th>Incontinence</th>
<th>Nutrition</th>
<th>Surface</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

### Signs to feel for

<table>
<thead>
<tr>
<th>(Tick if present)</th>
<th>Hard areas</th>
<th>Warm areas</th>
<th>Localised coolness if tissue death occurs</th>
<th>Swollen skin over bony points</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

### Signs to look for

<table>
<thead>
<tr>
<th>(Tick if present)</th>
<th>Non blanching Erythema</th>
<th>Blanching Erythema</th>
<th>Dry Scaly Skin</th>
<th>Oedema</th>
<th>Fragile</th>
<th>Healthy</th>
<th>History of skin tears</th>
<th>History of skin stripping by adhesive dressings</th>
<th>Skin care at life’s end</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td><strong>Date and Time</strong></td>
<td><strong>Date:</strong></td>
<td><strong>Time:</strong></td>
<td><strong>Date:</strong></td>
<td><strong>Time:</strong></td>
<td><strong>Date:</strong></td>
<td><strong>Time:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Focus of Care</strong></td>
<td>Skin</td>
<td>Keep moving</td>
<td>Skin</td>
<td>Keep moving</td>
<td>Skin</td>
<td>Keep moving</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Incontinence</td>
<td></td>
<td>Incontinence</td>
<td></td>
<td>Incontinence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nutrition</td>
<td></td>
<td>Nutrition</td>
<td></td>
<td>Nutrition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surface</td>
<td></td>
<td>Surface</td>
<td></td>
<td>Surface</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Signs to look for</strong></td>
<td>Red area</td>
<td></td>
<td>Red area</td>
<td></td>
<td>Red area</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Purplish/bluish area</td>
<td></td>
<td>Purplish/bluish area</td>
<td></td>
<td>Purplish/bluish area</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Area of discomfort/pain</td>
<td></td>
<td>Area of discomfort/pain</td>
<td></td>
<td>Area of discomfort/pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cracks, calluses</td>
<td></td>
<td>Cracks, calluses</td>
<td></td>
<td>Cracks, calluses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Localised oedema</td>
<td></td>
<td>Localised oedema</td>
<td></td>
<td>Localised oedema</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blisters</td>
<td></td>
<td>Blisters</td>
<td></td>
<td>Blisters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shiny areas</td>
<td></td>
<td>Shiny areas</td>
<td></td>
<td>Shiny areas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dry patches</td>
<td></td>
<td>Dry patches</td>
<td></td>
<td>Dry patches</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Signs to feel for</strong></td>
<td>Hard areas</td>
<td></td>
<td>Hard areas</td>
<td></td>
<td>Hard areas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Warm areas</td>
<td></td>
<td>Warm areas</td>
<td></td>
<td>Warm areas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Localised coolness if tissue death occurs</td>
<td></td>
<td>Localised coolness if tissue death occurs</td>
<td></td>
<td>Localised coolness if tissue death occurs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Swollen skin over bony points</td>
<td></td>
<td>Swollen skin over bony points</td>
<td></td>
<td>Swollen skin over bony points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Please note any further areas of damage that have occurred since initial assessment</strong></td>
<td>Signature:</td>
<td></td>
<td>Signature:</td>
<td></td>
<td>Signature:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema (distance from wound edge)</td>
<td>Blanching/non-blanching</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="image1.jpg" alt="Erythema" /></td>
<td><img src="image2.jpg" alt="Blanching" /></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Excoriated</th>
<th>Macerated</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image3.jpg" alt="Excoriated" /></td>
<td><img src="image4.jpg" alt="Macerated" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dry/Scaly</th>
<th>Oedematous</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image5.jpg" alt="Dry/Scaly" /></td>
<td><img src="image6.jpg" alt="Oedematous" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fragile/Delicate</th>
<th>Healthy</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image7.jpg" alt="Fragile/Delicate" /></td>
<td><img src="image8.jpg" alt="Healthy" /></td>
</tr>
<tr>
<td>Skin Stripping without Silicone Medical Adhesive Remover (SMAR)</td>
<td>Incontinence Associated dermatitis/Moisture damage</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rolled Edges</th>
<th>End of Life</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Other Assessment Tools:**

- For pressure ulcer please use grading tool
- For skin tears use STAR classification system
- Skin assessment reviewed with Waterlow score or as the patient’s condition changes

**Ask the patient and carers if there are any changes in skin condition since your last visit.**
**Management**

- Moisture Lesion
  - Wash gently with a low pH soap or a skin cleanser
  - Dry thoroughly by patting the skin
  - Use barrier protection
  - Use silicone-based dressings or films
  - Provide patient information

- Pressure Ulcer
  - Think SKINS:
    - Skin inspection
    - Keep moving
    - Incontinence
    - Nutrition
    - Surface

- Combination
  - Bring the two management plans together
  - Focus on pressure and moisture management

**Combination**

- A moisture lesion and a pressure ulcer may exist in the same area
- Where incontinence associated dermatitis/moisture lesions are accompanied by pressure, this must be reported as a pressure ulcer
- The two areas of moisture and pressure need to be addressed as part of their care plan

**Contact details for the Tissue Viability Department**

- **Jackie Stephen-Haynes** (Community)
  - Professor and Consultant Nurse in Tissue Viability
  - Email: j.stephen-haynes@wshs.net
  - Mobile: 07775 782775

- **Rosie Callaghan** (Community)
  - Tissue Viability Nurse
  - Email: rosie.callaghan@wshs.net
  - Mobile: 07717 543046

- **Jayne Alchurch** (Community)
  - Secretary, Tissue Viability
  - Email: jayne.alchurch@haow.nhs.uk
  - Phone Number: 01299 878453

- **Elaine Bethell** (Acute)
  - Lead Tissue Viability Nurse
  - Email: Elaine.Bethell@wocsaucrte.nhs.uk
  - Phone Number: 01905 763333 ext 33177

---

**Staff Guide to the Classification, Assessment and Management of Moisture Lesions and Pressure Ulcers**
# Staff Guide to the Classification, Assessment and Management of Moisture Lesions and Pressure Ulcers

## Management

<table>
<thead>
<tr>
<th>Moisture Lesion</th>
<th>Pressure Ulcer</th>
<th>Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Wash gently with a low pH soap or a skin cleanser</td>
<td>Think <strong>SKINS:</strong></td>
<td>• Bring the two management plans together</td>
</tr>
<tr>
<td>• Dry thoroughly by patting the skin</td>
<td><strong>Skin inspection</strong></td>
<td>• Focus on pressure and moisture management</td>
</tr>
<tr>
<td>• Utilise barrier protection</td>
<td>Keep moving</td>
<td></td>
</tr>
<tr>
<td>• Use silicone medical adhesive remover if required</td>
<td><strong>Incontinence</strong></td>
<td></td>
</tr>
<tr>
<td>• Provide patient information</td>
<td>Nutrition</td>
<td><strong>(food, hydration)</strong></td>
</tr>
<tr>
<td></td>
<td>Surface</td>
<td><strong>(bed, chair)</strong></td>
</tr>
</tbody>
</table>

## Reporting

<table>
<thead>
<tr>
<th>Moisture Lesion</th>
<th>Pressure Ulcer</th>
<th>Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not to be reported as a Serious Incident</td>
<td>Report all category 2 pressure ulcers as an incident, and all category 3 and 4 pressure ulcers as a Serious Incident on the Trust reporting system (<strong>Ulysses</strong>).</td>
<td>• Report all combination wounds as pressure ulcers</td>
</tr>
<tr>
<td>• Does not require a Root Cause Analysis</td>
<td>The use of a monisteam debrideent pad to assist with categorisation</td>
<td></td>
</tr>
<tr>
<td>• Refer for Specialist Tissue Viability / Continence Team if advice is required</td>
<td>Refer all category 3 and 4 pressure ulcers to Tissue Viability</td>
<td></td>
</tr>
</tbody>
</table>

### Combination

- A moisture lesion and a pressure ulcer may exist in the same area
- Where incontinence associated dermatitis/moisture lesions are accompanied by pressure, this must be reported as a pressure ulcer
- The two areas of moisture and pressure need to be addressed as part of their care plan

## Contact details for the Tissue Viability Department

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Email</th>
<th>Mobile</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jackie Stephen-Haynes (Community)</td>
<td>Professor and Consultant Nurse in Tissue Viability</td>
<td><a href="mailto:j.s.stephen-haynes@nhs.net">j.s.stephen-haynes@nhs.net</a></td>
<td>07776 7622776</td>
<td>01290 079063</td>
</tr>
<tr>
<td>Rose Callaghan (Community)</td>
<td>Tissue Viability Nurse</td>
<td><a href="mailto:r.callaghan@wh.nhs.uk">r.callaghan@wh.nhs.uk</a></td>
<td>07717 643946</td>
<td></td>
</tr>
<tr>
<td>Jayne Allchurch (Community)</td>
<td>Secretary, Tissue Viability</td>
<td><a href="mailto:j.allchurch@wh.nhs.uk">j.allchurch@wh.nhs.uk</a></td>
<td></td>
<td>01290 079063</td>
</tr>
<tr>
<td>Elaine Bellott (Acute)</td>
<td>Lead Tissue Viability Nurse</td>
<td><a href="mailto:e.bellott@wh.nhs.uk">e.bellott@wh.nhs.uk</a></td>
<td></td>
<td>01200 763333 ext 33177</td>
</tr>
</tbody>
</table>
How can skin breakdown be prevented?
It is possible to prevent skin damage or breakdown by maintaining mobility, managing incontinence, maintaining nutrition and regular skin care by using the appropriate skin care regime and products.

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Benefits</th>
<th>Precautions</th>
<th>Barrier Film</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balm additive</td>
<td>Soap substitute</td>
<td>Prevent dryness caused by soap based cleansers</td>
<td>Best used at night, can be taken to avoid slipping in the bath</td>
<td>×</td>
</tr>
<tr>
<td>Creams</td>
<td>Light moisturizer</td>
<td>Used for prevention or treatment</td>
<td>Do not overapply</td>
<td>×</td>
</tr>
<tr>
<td>Ointments</td>
<td>High oil content</td>
<td>Treatment for dry, thick, scaly skin</td>
<td>Do not overapply</td>
<td>×</td>
</tr>
<tr>
<td>Barrier Films</td>
<td>Barrier forming, durable</td>
<td>Protect skin against environmental factors e.g. friction, moisture</td>
<td>Apply sparingly</td>
<td>✓</td>
</tr>
<tr>
<td>Barrier Creams</td>
<td>Barrier forming, durable</td>
<td>Protect skin against environmental factors e.g. friction, moisture</td>
<td>Apply sparingly</td>
<td>✓</td>
</tr>
</tbody>
</table>

What can I do to help?
- Regularly inspect skin for signs of vulnerability
- Assess skin for redness and any signs of skin breakdown
- Wash your skin regularly with warm water and a mild, pH balanced cleanser
- Moisturise skin, especially dry areas with cream/ointments as advised by a health care professional
- Avoid “rubbing” the skin when applying creams
- Avoid damage to the skin through abrasions, tears etc.

Patient safety
An important aspect of patient safety is the promotion and maintenance of skin integrity which is one of the most important roles for clinicians in all care settings and must never be under prioritised - (Professor Stephen-Haynes 2011).
What is vulnerable skin?
Skin that is at risk of breakdown due to the loss of its natural protective barrier.

What factors increase the risk of skin damage?
- Lack of skin care
- Mobility
- Nutrition
- Incontinence
- Poor blood supply
- Smoking
- Environment/activity/lifestyle
- Underlying illness
- Trauma
- Drugs
- Steroids
- Age

What can cause skin damage?
- Friction and shear
- Pressure
- Dry skin
- Incontinence
- Skin Tears
- Excess moisture, e.g. from wounds, perspiration etc.

Skin assessment
Skin should be assessed with particular attention to the prominences such as the heels and sacrum. Redness is an indicator of early skin damage and actions should be taken to protect and prevent further damage:

S - Skin care
Cleansing and the use of appropriate protective barrier

K - Keep moving
Mobilisation and repositioning

I - Incontinence
Skin should be immediately cleansed and moisturised after each episode

N - Nutrition
Eating a well balanced diet and drinking plenty of fluids

What are the consequences of skin breakdown?
- Discomfort or pain
- Development of a wound
- Risk of wound infection
- Altered body image
- Reduced quality of life

Further advice is available from www.nhs.uk/Livewell/skin/Pages/Kepskinhealthy.aspx
# Equality Analysis

**Title of Policy/Function**

(Function Includes: Services; Projects; Strategy; Processes; Systems; Practices; Procedures; Protocols; Guidelines; Care Pathways etc..)

<table>
<thead>
<tr>
<th>New</th>
<th>Existing/Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revised</td>
</tr>
</tbody>
</table>

**Guideline for skin care in Tissue Viability**

**Short description of Policy/Function (aims and objectives, is the policy/function aimed at a particular group if so what is the intended benefit):**

This document has been produced to support Registered Healthcare Professionals working within Worcestershire Health & Care NHS Trust; it should be referred to for the recommended best practice for managing a patient with a skin tear.

The guideline will reduce potential risk and harm to patients with a skin tear.

The role of the Registered Health Care Professional will be defined in this guideline, outlining their responsibility and accountability for the patient with a skin tear.

<table>
<thead>
<tr>
<th>Name of Lead/Author(s)</th>
<th>Job Title</th>
<th>Contact details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Jackie Stephen-Haynes</td>
<td>Professor &amp; Consultant Tissue Viability Nurse</td>
<td><a href="mailto:j.stephen-haynes@nhs.net">j.stephen-haynes@nhs.net</a> 07775 792775</td>
</tr>
<tr>
<td>Rosie Callaghan</td>
<td>Tissue Viability Specialist Nurse</td>
<td><a href="mailto:r.callaghan@nhs.net">r.callaghan@nhs.net</a> 07717 543046</td>
</tr>
<tr>
<td>Monique Mariés</td>
<td>Tissue Viability Nurse</td>
<td><a href="mailto:Monique.maries@nhs.net">Monique.maries@nhs.net</a></td>
</tr>
<tr>
<td>Suzy Tandler</td>
<td>Tissue Viability Nurse</td>
<td><a href="mailto:Suzanne.tandler@nhs.net">Suzanne.tandler@nhs.net</a></td>
</tr>
</tbody>
</table>

When the policy/function involves patients/staff/partners/stakeholders etc. please where possible include them in the Equality Analysis to demonstrate openness, transparency and inclusion and particularly by those who this policy/function is most likely to have impact.

<table>
<thead>
<tr>
<th>Does this Policy/Function have any potential or actual impact that is positive(+) neutral (N) or negative (-) impact on the following protected characteristics please indicate:</th>
<th>+</th>
<th>N</th>
<th>-</th>
<th>Please provide a rational/justification for each of the following regardless of impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to age</td>
</tr>
<tr>
<td>Disability</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to disability</td>
</tr>
<tr>
<td>Gender Reassignment</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to gender reassignment</td>
</tr>
<tr>
<td>Pregnancy &amp; Maternity</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to pregnancy &amp; maternity</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to race</td>
</tr>
<tr>
<td>Religion &amp; Belief</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to religion &amp; belief</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to gender</td>
</tr>
<tr>
<td>Sexual orientation</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to sexual orientation</td>
</tr>
<tr>
<td>Marriage &amp; Civil Partnership</td>
<td></td>
<td>N</td>
<td></td>
<td>This policy is not relevant to marriage &amp; civil partnership</td>
</tr>
</tbody>
</table>
Other Groups who could experience inequality, e.g. carers, homeless, travelling communities, unemployed, people resident within deprived areas, different socio/economic groups e.g. low income families, asylum seekers/refugees, prisoners, people confined to closed institutions or community offenders, people with different work patterns e.g. part-time, full-time, job-share, short-term contractors or shift workers - Access, location and choice of venue, timings of events and activities. Support with caring responsibilities.

<table>
<thead>
<tr>
<th>Name</th>
<th>Job Title</th>
<th>Contact details</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Stephen-Haynes</td>
<td>Professor &amp; Consultant Tissue Viability Nurse</td>
<td><a href="mailto:j.stephen-haynes@nhs.net">j.stephen-haynes@nhs.net</a> 07775 792775</td>
</tr>
<tr>
<td>Rosie Callaghan</td>
<td>Tissue Viability Specialist Nurse</td>
<td><a href="mailto:r.callaghan@nhs.net">r.callaghan@nhs.net</a> 07717 543046</td>
</tr>
<tr>
<td>Monique Maries</td>
<td>Tissue Viability Nurse</td>
<td><a href="mailto:Monique.maries@nhs.net">Monique.maries@nhs.net</a></td>
</tr>
<tr>
<td>Suzy Tandler</td>
<td>Tissue Viability Nurse</td>
<td><a href="mailto:Suzanne.tandler@nhs.net">Suzanne.tandler@nhs.net</a></td>
</tr>
</tbody>
</table>

Start date of policy/function: December 2014
Period valid for: 24 months
Review date of policy/function: December 2016

If you have identified a potential discriminatory impact on the policy/function please refer it to the author together with suggestions to avoid or reduce the impact.

A copy of the completed Equality Analysis must be attached to the policy/function and a copy sent to:

Patrick McCloskey
Equality Inclusion Practitioner
Isaac Maddox House, Shrub Hill Road, Worcester, WR4 9RW
Tel: 01905 761324
Patrick.mccloskey@hacw.nhs.uk